Alps Advisors Inc Halozyme Therapeutics, Inc. Transaction History

Alps Advisors Inc

$14.8 Billion
Q3 2024

A detailed history of Alps Advisors Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 5,687 shares of HALO stock, worth $278,663. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,687

Previous 8,388 32.2%

Holding current value

$278,663

Previous $439,000 25.97%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$51.3 - $64.42 $138,561 - $173,998	-2,701 Reduced 32.2%	5,687 $325,000
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $1,701 - $2,358	-45 Reduced 0.53%	8,388 $439,000
Q1 2024 May 14, 2024	SELL	$33.68 - $41.95 $2,728 - $3,397	-81 Reduced 0.95%	8,433 $343,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $16,193 - $20,460	-486 Reduced 5.4%	8,514 $314,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $328,140 - $396,270	9,000 New	9,000 $343,000
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $1,241 - $1,842	-31 Reduced 0.4%	7,638 $434,000
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $295,486 - $397,100	7,669 New	7,669 $303,000
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $286,419 - $367,856	-8,959 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$31.82 - $40.75 $5,727 - $7,335	180 Added 2.05%	8,959 $360,000
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $337,728 - $407,521	8,779 New	8,779 $357,000
Q4 2019 Feb 07, 2020	SELL	$14.93 - $19.53 $4.36 Million - $5.7 Million	-291,765 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$15.2 - $17.69 $176,198 - $205,062	-11,592 Reduced 3.82%	291,765 $4.53 Million
Q2 2019 Aug 07, 2019	SELL	$14.75 - $17.26 $692,556 - $810,408	-46,953 Reduced 13.4%	303,357 $5.21 Million
Q1 2019 May 01, 2019	SELL	$13.94 - $17.58 $149,130 - $188,070	-10,698 Reduced 2.96%	350,310 $5.64 Million
Q4 2018 Feb 04, 2019	BUY	$13.33 - $18.66 $1.03 Million - $1.45 Million	77,631 Added 27.39%	361,008 $5.28 Million
Q3 2018 Oct 25, 2018	BUY	$16.68 - $18.41 $897,567 - $990,660	53,811 Added 23.44%	283,377 $5.15 Million
Q2 2018 Aug 02, 2018	BUY	$16.87 - $20.3 $1.21 Million - $1.46 Million	71,818 Added 45.53%	229,566 $3.87 Million
Q2 2018 Jul 25, 2018	SELL	$16.87 - $20.3 $963,428 - $1.16 Million	-57,109 Reduced 26.58%	157,748 $3.2 Million
Q1 2018 May 01, 2018	BUY	$17.06 - $21.2 $974,279 - $1.21 Million	57,109 Added 36.2%	214,857 $4.21 Million
Q4 2017 Feb 05, 2018	BUY	$16.75 - $20.8 $301,232 - $374,067	17,984 Added 12.87%	157,748 $3.2 Million
Q3 2017 Nov 03, 2017	BUY	$11.76 - $17.4 $1.64 Million - $2.43 Million	139,764	139,764 $2.43 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.83B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Halozyme Therapeutics, Inc. Transaction History